May 28, 2015 | The Israeli pharmaceutical company developing a drug for the treatment of multiple sclerosis, Mapi Pharma, announced that it raised $10 million in funding. Shavit Capital Fund led the round together with participation from Mapi CEO and Chairman Ehud Marom. Mapi is a developer of MS drug Copaxone and their version of the drug is administered once a month, in comparison to other delayed-release versions of the drug. Mapi Pharma was founded by Marom in 2008.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments